Need for guideline
The use of DMARDs in rheumatology and dermatology requires the use of guidelines for drug toxicity monitoring, as adverse effects can be significant in some patients. Most specialists recommend regular safety monitoring of these drugs based on clinical experience and the data from published literature, such as Product Specific Characteristics, the British National Formulary (BNF) and publications from various clinical trials in the specialty literature [3] [4] [5] [6] . The adverse effects of DMARDs as reported in research trials have limitations, as the patient characteristics are likely to be different from those in daily clinical practice. It is desirable if not necessary, to have some form of guideline which is multidisciplinary with patient participation, using evidence base, peer reviewed, well researched and supported by some study/audit of national practice. In 2000 the British Society for Rheumatology (BSR) produced its second edition of DMARD monitoring guidelines for rheumatologists but this was considered by the committee for evaluation of guidelines of the Royal College of Physicians to be more appropriate as a 'practical tool' than guideline. The need for a review of the guideline is, therefore, not only timely but also of paramount importance as the approach to therapy of many rheumatological and dermatological diseases has changed in the recent years, with greater accumulation of evidence since the last publication. Moreover, the current DMARD guideline has been developed in collaboration with the British Association of Dermatologists (BAD), as there is a common interest to prevent and limit toxicity associated with the use of these drugs in these two specialties.
Objective of the guideline
This guideline provides a list of licensed and unlicensed indications for the use of DMARDs in rheumatology and dermatology. It provides an evidence-based approach with appropriate references to all recommendations in terms of predicting, assessing and counteracting any toxic effects related to the use of the DMARDs in these two specialties.
The main objective of this guideline is to provide clear information that the responsible clinician can use to ensure DMARDs may be safely prescribed and monitored.
It is expected that the guidelines should be viewed with individual drug SPC's (Summary of Product Characteristics) and together will provide sufficient up-to-date knowledge about the DMARDs. This guideline also addresses many unresolved and evolving issues that can be considered as part of a research or audit, locally or nationally.
It is essential that clinicians remember to report (yellow card system) any serious adverse events (SAE) related to the use of DMARDs.
Target audience
This document is targeted at the following:
(1) Health care professionals in primary and secondary care. The areas the guideline does not cover (1) The management of DMARD therapy in children with inflammatory arthritis. The British Society for Paediatric and Adolescent Rheumatology (BSPAR) has produced guidelines [7] . (2) The management of the underlying disease for which the DMARD is prescribed. ( 3) The management of RA with immunotherapies, such as anti-TNF, anti-IL-1 and anti-B-cell therapy [8] . (4) This guideline does not advise specific monitoring profile for patients receiving 'combination' therapy. Where the monitoring schedule is different between the drugs used in combination, it is advised to adopt a more stringent monitoring schedule based on clinical judgement. (5) This guideline does not advise on the management of patients on cyclophosphamide, as this drug is more commonly used in the treatment of vasculitis and will be discussed in the guideline for the management of adults with vasculitis [9] . (6) Immunization: It is beyond the scope of this guideline to give detailed advice on immunization in patients treated with DMARDs, as there is insufficient evidence about the degree of immunosuppression induced by the drugs. However, some general principles have been mentioned. The advice on immunization, particularly against encapsulated organism, such as pneumovax, has been mentioned on the website of the Health Protection Agency. As guidelines are evolving, in difficult cases it is advisable to discuss with the Health Protection Agency, or check their website, for further advice (Prof. Liz Miller, Centre for Infectious Disease and Immunisation, Colindale, London, personal communication).
Involvement of other people or organizations including user representative organizations and pharmaceutical companies in the development of the guideline
This guideline was developed in collaboration with the NRAS. Patient surveys related to DMARD treatments and the patients' perspectives have been included [10] . No representatives of pharmaceutical companies were involved in guideline development.
Rigour of development
Statement of scope of literature search and strategy employed used were relevant to each section of the guideline. Evidence was graded according to the strength of literature to support each statement, using the grading suggested by the Royal College of Physicians of London [11] and the document was prepared in accordance with the principles outlined in the Appraisal of Guidelines Research and Evaluation (AGREE) guidelines [12] .
Statement of any limit of search
The literature search was confined to new evidence since the previous guideline was produced in 2000 and non-English literature was not reviewed.
Statement of when the guideline will be updated
It is expected that the guideline will be updated after another 5 yrs.
Guideline itself

Eligibility criteria
The eligibility of a patient to receive DMARD therapy will be at the discretion of the prescribing physician after full discussion with the patient about the potential benefits and adverse effects of the therapy. The statements made in this guideline should be considered in conjunction with the guideline on the management of RA [13] .
Exclusion criteria
The prescribing physician is responsible for identifying patients who should not receive DMARD therapy. For example, many of the drugs are not suitable for people considering starting a family, and this will be discussed with each drug.
Assessment of disease and response to treatment
This is detailed in the Guideline for the Management of RA [13] .
It is important to note that monitoring carried out for assessing side effects to the therapy can also be useful in monitoring treatment response.
Criteria for withdrawal of therapy
The two common reasons for withdrawal of any drug therapy are inefficacy and adverse effects of the drug and are equally applicable to all the drugs in this guideline. Temporary withdrawal is advised in some clinical circumstances if patients develop an untoward side effect or in some physiological conditions e.g. pregnancy/lactation/severe acute illness.
General principles
DMARDs are slow acting drugs which may take weeks to months to produce any clinical response. Patients need to be informed about the delayed action of these drugs and the need to persevere with the treatment (in the absence of side effect). Compliance with DMARDs therapy improves when patients follow a mutually agreed recommendation [14, 15] . Combination therapies with DMARDs may be initiated in a 'sequential step up' approach in patients not responding to monotherapy. Alternatively, 'step down' therapy may be undertaken when combination therapy was commenced in the early phase of the disease [13] .
The monitoring requirements for each drug are described fully. Where monitoring requirements differ between rheumatological and dermatological conditions, the differences are clearly highlighted in the schedule for the individual drug.
The key statements when monitoring a DMARD are:
( The following DMARDs are discussed in this document 
Applicability and utility
A statement of potential organizational barriers to introduction
These guidelines are timely as current changes in healthcare provision and monitoring have an impact on patient management.
The development of this guideline will support care of patients receiving DMARDs in both primary and secondary care, through the national programme of 'near patient testing'.
Programmes for DMARD therapy monitoring are already in existence, usually shared with primary care. It is therefore not anticipated that there will be significant organizational barriers to introduction of the recommendations detailed in this guideline.
Potential cost implications for the introduction of guideline
Significant costs will be incurred to ensure that there are robust means to act on the results of the monitoring programme. Other costs will be guideline distribution and the provision of a local means of sharing the results through patient-held booklets or IT systems.
Mechanism for the audit of guideline
Audit will be very important, as the guideline lacks good evidence in many areas. Suggested audit topics are described with each therapy.
Appendices
Working party membership, affiliations and conflicts of interest
The working party was set up independently of any input or funding from the manufacturers of the DMARDs included in the guideline. Members of the working party were asked to clarify their relationship with the pharmaceutical companies. Members were asked to declare if they, as individuals, had been sponsored to attend scientific or other meetings in the past 24 months, or if they had a direct financial stake in the manufacturing companies.
They were also asked if their units had received funding from the manufacturers to take part in clinical trials of any of the drugs in the DMARD guidelines. 
References with indication of level of evidence
The guidelines are referenced and graded according to the AGREE and Royal College of Physicians concise guidance to good practice [11, 12] .
A ¼ Evidence from at least one properly performed, randomized controlled trial or meta-analysis of several controlled trials.
B ¼ Well-conducted clinical studies, but no randomized clinical trials; evidence may be extensive but essentially descriptive.
C ¼ Evidence obtained from expert committee reports or opinions, and/or clinical experience of respected authorities. This grading indicates an absence of directly applicable studies of good quality.
Summary
DMARDs
DMARDs are fundamental to arresting the disease process in RA and other inflammatory arthritides. Many are also used for other licensed and unlicensed indications, such as chronic inflammatory skin or bowel disease. While early initiation of therapy is essential to arrest RA, sustained use is vital if disease suppression is to be maintained, and so these drugs may be used for an unlimited period of time. Prolonged therapy requires long-term monitoring for toxicity and safety profile.
Whatever DMARD is considered appropriate for a patient, it is paramount that the patient is carefully monitored so that there is no delay in the detection of any untoward effect of the drug. Monitoring will also contribute to assessing activity of the underlying disease. J. Caveats:
Auranofin
(1) Immunization [7] : (a) Women of childbearing potential should be advised to use effective contraceptive precautions. Evidence of mutagenicity is equivocal in men. In most cases, azathioprine should not be prescribed if there is a possibility of pregnancy, although there may be some circumstances where the benefit of continuing treatment outweighs the possible risks related to the unborn child. A careful assessment of risk vs benefit is advised. Dose reduction at 32 weeks of gestation may prevent neonatal leucopenia. (b) Women treated with azathioprine should not breast feed [3, 4, 8, 9] . (3) TPMT assay: This assay provides additional information of risks related to treatment but does not replace routine monitoring [10, 11] . However, for those with higher levels of serum TPMT, higher doses of azathioprine may be required. Homozygous deficiency is associated with serious and fatal toxicity that may occur within 6 weeks of starting azathioprine [11] . Heterozygous deficiency is also linked to serious adverse events, although the symptoms may not be evident until 6 months after commencing treatment. Minor unrecognized infections or drug interactions, particularly when co-prescribed with aminosalicylates, such as sulfasalazine, mesalazine or olsalazine, may precipitate fatal toxicity. Heterozygous individuals should be prescribed azathioprine with caution and, in particular, reduced drug dosage.
K. Unresolved and evolving issues: These issues could be considered for future randomized clinical trials or audits locally, regionally or nationally.
(1) Role of TPMT in predicting haemato-toxicity in rheumatological diseases? (2) Is there any relationship of azathioprine and skin or cervical cancer? (3) The safety of azathioprine in pregnancy? (4) Is there any association between azathioprine and pancreatitis?
References Azathioprine [5, 6] .
(2) Grapefruit including grapefruit juice must be avoided for 1 h before or after taking ciclosporin tablets as bioavailability is increased [2] . (3) Malignancy such as lymphomas, etc [4, 6] . F. Contraindications: Grade of evidence: C (1) Uncontrolled hypertension [1, 4, [6] [7] [8] .
(2) Renal and liver failure (in patients with RA) [6] . (3) Severe electrolyte imbalance i.e. hyperkalemia [1, 2] . (4) Suspected systemic infection or sepsis [6] . G. Notable drug interaction (refer to BNF and SPC)
(1) Diclofenac: Reduce the dose of diclofenac by 50% [1] [2] [3] (2) Colchicine: To be avoided [1, 2] . (3) Simvastatin: maximum dose 10 mg/day [6] . (4) Nifedipine: use with caution [6] . (5) Digoxin: May increase the serum levels of digoxin [6] . (6) St. John's Wort: decreases ciclosporin activity [6] . (7) I. Actions to be taken: Grade of evidence: C [2, 7] . Late rashes are more serious than early ones [4, 5] .
Withhold until discussed with specialist team.
Nausea
Taking medication before bed may reduce nausea. Alteration of taste [2, 7] Continue treatment (may settle spontaneously). Abnormal bruising or severe sore throat [2, 7] Check FBC immediately and withhold until results are available. NB. Simple dose reduction is unlikely to produce a rapid diminution of adverse effects as the half-life of the drug is 2 weeks (1-4 weeks) . If a rapid response is required, consider washoutsee section J.
References D-Penicillamine
I. Caveats or shingles, passive immunisation should be carried out using VZIG.
(2) Pregnancy and lactation: Leflunomide is teratogenic and must not be given to pregnant women or women of child bearing potential unless reliable contraception is used. Women planning to have children should either discontinue the drug 2 yrs prior to conception [2, 3] or have a rapid removal of its active metabolite by following the washout procedure. Men should use effective contraception for 3 months after stopping leflunomide [3] .
(a) Blood concentrations should be checked prior to planned pregnancy especially if within 2 years of stopping leflunomide or following wash out [2, 3] . Any pregnancy within 2 yrs of discontinuation of leflunomide should be discussed with rheumatologist if drug washout has not been performed [2, 3] . Notify pharmaceutical company in the event of pregnancy while on leflunomide [3] . (b) Breast feeding should be avoided as animal studies indicate that metabolites of leflunomide are secreted in the breast milk [2] . (3) Hepatic toxicity: Leflunomide is a potentially hepatotoxic drug and caution is advised when using leflunomide concomitantly with another hepatotoxic drug, such as methotrexate, or if there is evidence of current or recent hepatitis with Hepatitis B or C viruses [3, 4, [6] [7] [8] [9] . Rare cases of severe liver injury (some with fatal outcome) have been reported during treatment with leflunomide. Most cases occurred within 6 months and in a setting of multiple risk factors for hepatotoxicity [9, 10] . It is highly recommended that LFTs be monitored closely (at least once a month) if leflunomide is co-prescribed with potentially hepatotoxic drugs, such as methotrexate [5, 9, 10] . Patient should be asked to limit alcohol intake well within national limits 4-8 units a week (National Survey data 2005). (4) Drug interactions: Leflunomide can interact with many drugs, particularly with phenytoin, tolbutamide and may enhance the effects of these drugs [1] [2] [3] although significant interaction is unlikely [5] . Leflunomide also interacts with warfarin and the International normal ratio (INR) should be very closely monitored for several weeks even after stopping the leflunomide. As leflunomide has an extremely long half-life (2 weeks) the interactions can potentially be serious and more actions may be required beside just discontinuation of the drug such as washout. This may be of practical importance when changing from leflunomide to another DMARD. (5) GI effects: Diarrhoea often occurs early in therapy when full loading doses of 100 mg/day for 3 days are given. Such effects lead to patient dissatisfaction and issues related to compliance and subsequent withdrawal of the drug in some circumstances. Omission of loading dose is acceptable with the knowledge that there may be a slight delay in response time. (6) Hypertension: Regular monitoring of blood pressure is necessary during treatment and if there is a significant rise in blood pressure, then this should be treated. However, it is important to undertake a risk -benefit assessment at all times. In severe uncontrolled cases it is necessary to consider stopping the drug and washout if necessary. (7) Infections: Any infection should be treated on its own merit.
All types of infection can occur and a cautious vigilance is necessary to detect early evidence of infection. (8) Pulmonary infiltration/pneumonitis/reactions: Pulmonary infiltration/pneumonitis as an acute allergic reaction has been described in a small number of patients after starting leflunomide [12] [13] [14] [15] [16] . Patients should be made aware of this rare complication (see drug SPC) and if they become short of breath they should stop the tablets at once and seek urgent medical advice. If combination therapy is used with methotrexate, the patient should be made aware of the possible added risk even though this may not be clinically significant (Dr Clive Kelly, Gateshead Hospital, personal communication).
J. Washout procedure: Grade of evidence: C To aid drug elimination in cases of serious adverse effect or before conception, stop treatment and give either cholestyramine 8 g three times daily for 11 days or activated charcoal 50 g four times daily for 11 days; the concentration of active metabolite after washout should be less than 20 g/l (measured on two occasions 14 days apart) in men and women before conception (consult product literature). [6] . B1. Methotrexate dosage: Grade of evidence: C Typical dose: 7.5-25 mg ONCE weekly; starting dose may vary depending on the severity of the condition and patient characteristics such as age, renal function and other comorbid conditions. The initial dose may be 5-10 mg once weekly, increasing by 2.5-5 mg every 2-6 weeks until disease stabilized [7] . The maximum licensed dose in RA is 25 mg/week. Rarely, the maximum dose can be 30 mg/week [8] . Lower doses should be considered for frail elderly patients who often have poor renal function. If maximum oral dose is not effective or causes intolerance, consider i.m. or subcutaneous route of administration before discontinuation of the drug.
B2. Folic acid: Grade of evidence: A Typical dose: 5 mg once weekly, preferably the day after the methotrexate [9] . Folic acid can be given any day as long as it is not on the same day as methotrexate. Folic acid reduces toxic effects and improves continuation of therapy and compliance [9] [10] [11] .
C. Route of administration Methotrexate: Oral, i.m., i.v. or subcutaneous Oral (licensed): It is preferable to use only 2.5 mg tablets and patients should be reminded of the need to check the dose and strength of the tablets with each prescription. Parenteral (licensed): The dose for parenteral use is usually the same as the oral although one should consider the difference in bioavailibility between oral and parenteral routes of administration. [12] . Re: Serum pro-collagen III in patients with psoriatic arthritis-refer section J.
CXR: chest X-ray.
I. Actions to be taken: Grade of evidence: C [13] WBC <3. J. Special clinical circumstances:
(1) Alcohol: Any patient suspected of alcohol abuse is usually unsuitable for methotrexate therapy. Dermatologists (BAD) may allow patients, receiving methotrexate, to continue taking small amounts of alcohol (4-6 units/week) [17] . Rheumatologists should advise the patients receiving methotrexate to limit their alcohol intake well within national recommendations. (2) Hepatotoxicity: Methotrexate related hepatotoxicity was first reported in psoriasis patients several decades ago. A cumulative dose of 1.5 g of methotrexate might cause clinically significant liver disease [34] . Please note that liver fibrosis/cirrhosis may occur with normal liver enzymes and imaging findings [34, 35] . (a) Liver biopsy: Grade of evidence: B Current studies in patients with RA suggest that liver biopsies are not cost effective for at least the first 10 yrs of methotrexate use in patients with normal liver function values [8] . Clinically serious liver disease (CSLD) is rarely seen in RA patients receiving low dose methotrexate and routine liver biopsies are therefore not recommended [16] . BAD does not recommend routine liver biopsy on all patients receiving methotrexate. However, if there is history of pre-existing liver disease, a baseline ultrasound guided liver biopsy should be performed. This should be undertaken soon after the methotrexate is started, usually within 3-4 months [34, 35] . (b) Serum pro-collagen III levels: Grade of evidence: B Dermatologists (BAD) have recently examined the role of serological markers such as pro-collagen III amino terminal peptide (PIIINP) in detecting methotrexateinduced liver damage. A recent study suggests that the patients with repeated normal levels of PIIINP are very unlikely to have significant liver damage from fibrosis/cirrhosis [17] and that follow-up liver biopsies may only be offered to patients with persistently abnormal levels of PIIINP over 4.2 ng/ml (for Orion assay)-section M2.
In rheumatology, the role of such serological markers is unclear as it can be false positive in inflammatory arthritis, such as rheumatoid or psoriatic arthritis [18] . (3) Pulmonary toxicity: Pulmonary toxicity related to methotrexate is often the cause for withdrawal of therapy in an otherwise stable patient with a frequency of 1:108 patient years compared with 1: 35 patient years for hepatotoxicity [21] and 1: 58 patient years for neutropenia [36] . Methotrexate pneumonitis (MP) is a potentially fatal hypersensitivity reaction and is far less predictable than hepatic or haematological toxicity. It is most frequently but not exclusively seen within the first year of treatment [28] . Many studies suggest that the incidence of MP is much higher in patients with pre-existing lung disease [20] [21] [22] [23] [24] [25] [26] [27] . (4) Pulmonary Function Test (PFT): Grade of evidence: B PFT may be a useful investigation to detect pre-existing lung disease and is a sensitive but non-specific test in identifying occult lung disease. If pre-treatment CXR suggests abnormal shadowing it may be worth considering a high resolution computerized scan (HRCT) and PFT to ascertain the carbon monoxide transfer factor (TLCO) prior to commencing methotrexate therapy [26] . One recent study suggests carbon monoxide transfer factor (TLCO) is a more sensitive marker for detection of Interstitial Lung Disease (ILD) than CXR [36, 37] . In fact the study proposes the use of PFT as a screening test and recommends that patients with a TLCO value <70% should be subjected to a HRCT (and CXR) [27] . It is important to note that airway obstruction may not be a contraindication to the use of methotrexate but presence of interstitial lung disease certainly is, and it is better detected prior to commencement of therapy or avoided (Dr Clive Kelly, Gateshead Hospital, personal communication). (c) Consider immediate discussion with supervising specialist/team, medical on-call team or the local haematologist. However, in cytopenia due to Felty's syndromemethotrexate might be a useful drug with good haematological outcome [6] . (6) Pregnancy and breast feeding: Grade of evidence: C All patients, male and female, should be advised against conception and pregnancy during treatment with methotrexate as it is an abortificient as well as a teratogenic drug. If patients become pregnant inadvertently, it is appropriate to refer the patient to an obstetrician. Breast feeding should not be allowed as the drug may be excreted in the breast milk. Patients should be advised to continue contraception for at least 3 months after stopping methotrexate [30, 31] . (7) Surgical interventions: Grade of evidence: A Earlier studies suggested an increased incidence of early post-operative complications, such as infections, in a significant number of patients who continued their treatment with methotrexate within 4 weeks of surgery. Two recent studies, one prospective randomized controlled, suggest that the continuation of methotrexate treatment does not increase the risk of infection or surgical complications in patients with RA [32, 33] . (8) NSAIDs: Grade of evidence: C NSAIDs can be continued as long as monitoring is regularly undertaken. Special cautions need to be exercised if significant abnormalities are noted in liver enzymes. All patients should be regularly advised to avoid over the counter medications including aspirin and ibuprofen [2] without the knowledge of the specialist team. (9) Infections: Grade of evidence: B In contrast to many immunosuppressive therapies, methotrexate is relatively safe and has a low risk of infection associated with its use [38] . However, infections are still reported and such infections need to be diagnosed at an early stage to prevent systemic dissemination, and methotrexate should be stopped immediately. If infection is associated with dehydration and pre-renal failure, stop methotrexate and consider folinic acid rescue. The infections can be due to a range of organisms, from viral and bacterial to rare opportunistic infections. One recent short-term observational study (over 6 months) showed a high death rate (33%) in patients with pulmonary infections [39] . Significant mortality and morbidity can be associated with viral infections due to Herpes Zoster/Varicella. The decision whether to perform liver biopsy, withdraw or continue treatment despite raised PIIINP levels must also take into account other factors, such as disease severity, patient age and the ease with which alternative therapies may be used in place of methotrexate.
Mycophenolate mofetil
Mycophenolate mofetil (MMF) is a pro-drug of the active metabolite of mycophenolic acid. It is a suppressor of T and B cell proliferation and adhesion and inhibits inosine monophosphate dehydrogenase that eventually blocks the progression to DNA synthesis and proliferation [1] . It does not inhibit the production of interleukins as does ciclosporin and tacrolimus. MMF has routinely been used in organ transplantation for many years and this remains the licensed indication for its use. A. Indications: (Unlicensed) RA [2] , systemic lupus erythematosus and lupus nephritis [3] and inflammatory myopathy such as dermatomyositis and polymyositis [4, 5] . It has also been used in psoriasis [6] , atopic dermatitis and autoimmune bullous dermatoses such as pemphigus. It is also being used in randomized clinical trials in scleroderma, vasculitis and Behc¸et's disease (Prof. Chris Denton, Royal Free Hospital, London, personal communication). B. Mycophenolate mofetil dosage: Grade of evidence: C Typical dose: 1-2 g/day.
Starting dose: 500 mg daily for the 1st week, 500 mg twice daily for the 2nd week and increase it gradually by 500 mg
